Roche Holding AG ASH Medical Congress Virtual Event Transcript
(Operator Instructions) One last remark, if you would like to follow the presented slides on your end as well, feel free to go to roche.com/investors to download the presentation. At this time, it's my pleasure to introduce you to Bruno Eschli, Head of Investor Relations. Bruno, the stage is yours.
Thanks, Henrik, for the introduction. Can I have the first slide, please?
So welcome to our last IR call for this year, where we would like to provide you an in-depth insight in our growing hematology franchise. And let me first quickly take you for today's agenda. We have several speakers with us joining. The first section will be with Peter Ahnesorg. Peter is our Franchise Head, hematology and Global Product Strategy, and he will present our malignant and nonmalignant hematology strategy and the overall portfolio.
The second part then goes to Charles Fuchs, our Global Head of Oncology and Hematology and Product Development, and Charlie will take you through the key data presented at ASH '22. And finally
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |